Endometrial hyperplasia screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Endometrial hyperplasia}}
{{Endometrial hyperplasia}}
{{CMG}}{{AE}} {{Badria}} , {{STM}}
{{CMG}}{{AE}} {{Swathi}}


==Oveview==
==Oveview==
Routine screening for endometrial hyperplasia or endometrial carcinoma is not recommended.
Routine [[Screening (medicine)|screening]] for [[endometrial]] [[hyperplasia]] or [[endometrial]] [[carcinoma]] is not recommended.


==Screening==
==Screening==
* Women receiving unopposed [[Estrogen|estrogens]] should undergo [[endometrial]] sampling once every 2 years. <ref name="pmid1893367">{{cite journal |vauthors=Hakala T, Mecklin JP, Forss M, Järvinen H, Lehtovirta P |title=Endometrial carcinoma in the cancer family syndrome |journal=Cancer |volume=68 |issue=7 |pages=1656–9 |date=October 1991 |pmid=1893367 |doi= |url=}}</ref>
* [[Women]] receiving unopposed [[Estrogen|estrogens]] should undergo [[endometrial]] [[sampling]] once every 2 [[Year|years]]. <ref name="pmid1893367">{{cite journal |vauthors=Hakala T, Mecklin JP, Forss M, Järvinen H, Lehtovirta P |title=Endometrial carcinoma in the cancer family syndrome |journal=Cancer |volume=68 |issue=7 |pages=1656–9 |date=October 1991 |pmid=1893367 |doi= |url=}}</ref>
* Particularly if [[endometrial]] hyperstimulation was documented previously and is not been treated by short-term progestins.  
* Particularly if [[endometrial]] hyperstimulation was documented previously and is not been treated by short-term [[progestins]].  
* If high-risk individual requests an [[endometrial]] evaluation before or during [[HRT]].  
* If high-risk individual requests an [[endometrial]] evaluation before or during [[HRT]].  
* Women at high risk for [[Endometrial cancer|endometrial carcinoma]], such as history of [[Lynch II syndrome]].
* [[Women]] at high risk for [[Endometrial cancer|endometrial carcinoma]], such as history of [[Lynch II syndrome]].


==References==
==References==

Latest revision as of 13:12, 8 May 2019

Endometrial hyperplasia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Endometrial hyperplasia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Case Studies

Case #1

Endometrial hyperplasia screening On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Endometrial hyperplasia screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Endometrial hyperplasia screening

CDC on Endometrial hyperplasia screening

Endometrial hyperplasia screening in the news

Blogs on Endometrial hyperplasia screening

Directions to Hospitals Treating Endometrial hyperplasia

Risk calculators and risk factors for Endometrial hyperplasia screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Swathi Venkatesan, M.B.B.S.[2]

Oveview

Routine screening for endometrial hyperplasia or endometrial carcinoma is not recommended.

Screening

References

  1. Hakala T, Mecklin JP, Forss M, Järvinen H, Lehtovirta P (October 1991). "Endometrial carcinoma in the cancer family syndrome". Cancer. 68 (7): 1656–9. PMID 1893367.

Template:WikiDoc Sources